Home / Health / Heart Attack Recovery Boosted by Weight-Loss Drugs
Heart Attack Recovery Boosted by Weight-Loss Drugs
3 Mar
Summary
- GLP-1 drugs may prevent 'no-reflow' complication after heart attacks.
- Research based on animal models shows promising results for heart recovery.
- Paramedics could potentially administer these drugs to patients.
New research indicates that GLP-1 weight-loss drugs, such as Ozempic and Wegovy, may offer a promising new approach to improving recovery for heart attack patients. These medications could potentially prevent a complication known as 'no-reflow'.
This 'no-reflow' phenomenon affects nearly half of heart attack patients, where tiny blood vessels in the heart remain narrowed even after emergency treatment. This prevents sufficient blood from reaching certain areas of the heart tissue, increasing the risk of death or hospital readmission.
Experts from the British Heart Foundation and University College London conducted the study, which was based on animal model trials. The findings suggest that GLP-1 drugs might prevent this issue, offering a potentially life-saving solution.
While the results are encouraging, further studies involving humans are required to confirm these benefits. If successful, these drugs could eventually be administered by paramedics en route to the hospital or during artery reopening procedures.
